二甲双胍与不同分子亚型乳腺癌的关系

doi:10.11904/j.issn.1002-3070.2018.03.016

实用肿瘤学杂志 ›› 2018, Vol. 32 ›› Issue (3): 267-270.doi: 10.11904/j.issn.1002-3070.2018.03.016

二甲双胍与不同分子亚型乳腺癌的关系

李林(综述), 李志高(审校)

哈尔滨医科大学附属肿瘤医院乳腺外科二病区(哈尔滨 150081)

收稿日期:2018-01-07 出版日期:2018-07-10 发布日期:2018-07-10
通讯作者: 李志高,E-mail:drzhigaoli@126.com
作者简介:李林,男,(1993-),硕士研究生,从事二甲双胍与乳腺癌关系的研究
基金资助:
海燕科研基金(编号:JJZD2016-05)

The relationship between metformin and different molecular subtypes of breast cancer

LI Lin,LI Zhigao

Department of Oncology,Harbin Medical University Cancer Hospital,Harbin 150081,China

Received:2018-01-07 Online:2018-07-10 Published:2018-07-10

摘要/Abstract

摘要： 二甲双胍做为糖尿病治疗的一线用药,不仅可以降低血糖,还能促使乳腺癌细胞凋亡。体内外实验证实了二甲双胍对各型乳腺癌的抑制作用,而且二甲双胍还能在新辅助化疗以及放疗中协同治疗乳腺癌。本文将对二甲双胍在乳腺癌治疗中的研究进展做一综述。

关键词: 二甲双胍, 乳腺癌, 治疗

Abstract: Metformin as the first-line medication for diabetes treatment can not only reduce blood sugar,but it also induces apoptosis in breast cancer cells.The effect and mechanism of metformin on various types of breast cancer are confirmed by in vitro and in vivo,and metformin can also co-treat breast cancer in neoadjuvant chemotherapy and radiotherapy.This article will review the progress of metformin in the treatment of breast cancer.

Key words: Metformin, Breast cancer, Treatment

中图分类号:

R737.9

李林(综述), 李志高(审校). 二甲双胍与不同分子亚型乳腺癌的关系[J]. 实用肿瘤学杂志, 2018, 32(3): 267-270.

LI Lin, LI Zhigao. The relationship between metformin and different molecular subtypes of breast cancer[J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(3): 267-270.

参考文献

1 González N,PrietoI,Del Puerto-Nevado L,et al.2017 update on the relationship between diabetes and colorectal cancer:epidemiology,potential molecular mechanisms and therapeutic implications[J].Oncotarget,2017,8(11):18456-18485.
2 Yu X,Mao W,Zhai Y,et al.Anti-tumor activity of metformin:from metabolic and epigenetic perspectives[J].Oncotarget,2017,8(3):5619-5628.
3 Tseng CH.Rosiglitazone reduces breast cancer risk in Taiwanese female patients with type 2 diabetes mellitus[J].Oncotarget,2017,8(2):3042-3048.
4 Cai H,Zhang Y,Han TK,et al.Cation-selective transporters are critical to the AMPK-mediated antiproliferative effects of metformin in human breast cancer cells[J].Int J Cancer,2016,138(9):2281-2292.
5 Pulito C,Donzelli S,Muti P,et al.microRNAs and cancer metabolism reprogramming:the paradigm of metformin[J].Ann Trans Med,2014,2(6):58.
6 Gdowski A,Panchoo M,Treuren TV.Emerging therapeutics for targeting Akt in cancer[J].Front Biosci,2016,21:757-768.
7 Liu S,Chen S,Yuan W,et al.PD-1/PD-L1 interaction up-regulates MDR1/P-gp expression in breast cancer cells via PI3K/Akt and MAPK/ERK pathways[J].Oncotarget,2017,8(59):99901-99912.
8 Zhang J,Li G,Chen Y,et al.Metformin in hibits tumorigenesis and tumor growth of breast cancer cells by upregulating miR-200c but downregulating Akt2 expression[J].J Cancer,2017,8(10):1849-1864.
9 Thakur SS,LiH,Chan AMY,et al.The use of automated Ki67 analysis to predict Oncotype DX risk-of-recurrence categories in early-stage breast cancer[J].PLoS One,2018,13(1):e0188983.
10 DeCensi A,Guerrieri-Gonzaga A,Gandini S,et al.Prognostic significance of Ki-67 labeling index after short-term presurgical tamoxifen in women with ER-positive breast cancer[J].Ann Oncol,2011,22(3):582-587.
11 Bonanni B,Puntoni M,Cazzaniga M,et al.Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial[J].J Clin Oncol,2012,30(21):2593-2600.
12 Chen S,Yao F,Xiao Q,et al.EZH2 inhibition sensitizes tamoxifen resistant breast cancer cells through cell cycle regulation[J].Mol Med Rep,2018,17(2):2642-2650.
13 Kim J,Lee J,Jang SY,et al.Anticancer effect of metformin on estrogen receptor-positive and tamoxifen-resistant breast cancer cell lines[J].Oncol Rep,2016,35(5):2553-2560.
14 Engels CC,deGlas NA,Sajet A,et al.The influence of insulin-like growth factor-1-receptor expression and endocrine treatment on clinical outcome of postmenopausal hormone receptor positive breast cancer patients:A Dutch TEAM substudy analysis[J].Mol Oncol,2016,10(4):509-516.
15 Hadad SM,Hardie DG,Appleyard V.Effects of metformin on breast cancer cell proliferation,the AMPK pathway and the cell cycle[J].Clin Transl Oncol,2014,16(8):746-752.
16 Scherbakov AM,Sorokin DV,Tatarskiy VV,et al.The phenomenon of acquired resistance to metformin in breast cancer cells:The interaction of growth pathways and estrogen receptor signaling[J].IUBMB Life,2016,68(4):281-292.
17 Parris AB,Zhao Q,Howard EW,et al.Buformin inhibits the stemness of erbB-2-overexpressing breast cancer cells and premalignant mammary tissues of MMTV-erbB-2 transgenic mice[J].J Exp Clin Cancer Res,2017,36(1):28.
18 Sheng Q,Liu X,Fleming E,et al.An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells[J].Cancer Cell,2010,17(3):298-310.
19 Wilson TR,Lee DY,Berry L,et al.Neuregulin-1-mediated autocrine signaling underlies sensitivity to HER2 kinase inhibitors in a subset of human cancers[J].Cancer Cell,2011,20(2):158-172.
20 Kim J,Lee J,Kim C,et al.Anti-cancer effect of metformin by suppressing signaling pathway of HER2 and HER3 in tamoxifen-resistant breast cancer cells[J].Tumour Biol,2016,37(5):5811-5819.
21 David CJ,Huang YH,Chen M,et al.TGF-β tumor suppression through a lethal EMT[J].Cell,2016,164(5):1015-1030.
22 Morales DR.Metformin in cancer treatment and prevention[J].Annu Rev Med,2015,66:17-29.
23 Wahdan-Alaswad R,Harrell JC,Fan Z,et al.Metformin attenuates transforming growth factor beta(TGF-β)mediated oncogenesis in mesenchymal stem-like/claudin-low triple negative breast cancer[J].Cell Cycle,2016,15(8):1046-1059.
24 Shi P,Liu W,Wang H,et al.Metformin suppresses triple-negative breast cancer stem cells by targeting KLF5 for degradation[J].Cell Discov,2017,3:17010.
25 Niraula S,Dowling RJ,Ennis M,et al.Metformin in early breast cancer:a prospective window of opportunity neoadjuvant study[J].Breast Cancer Res Treat,2012,135(3):821-830.
26 Zhang Y,Storr SJ,Johnson K,et al.Involvement of metformin and AMPK in the radioresponse and prognosis of luminal versus basal-like breast cancer treated with radiotherapy[J].Oncotarget,2014,5(24):12936-12949.
27 Ferro A,Goyal S,Kim S,et al.Evaluation of diabetic patients with breast cancer treated with metformin during adjuvant radiotherapy[J].Int J Cancer,2013,2013:659723.

[1]	王晓雅,肖斌,廖扬,唐荣芝,孙朝晖,李林海. CXCR家族蛋白在不同乳腺癌亚型中的表达及临床预后分析[J]. 实用肿瘤学杂志, 2019, 33(3): 206-210.
[2]	李烁,张楠楠,李亮亮,龙志平,尹慧慧,赵亚双,王帆. 外周血白细胞PDE4C基因甲基化及环境因素交互作用与乳腺癌发病的关系[J]. 实用肿瘤学杂志, 2019, 33(3): 233-238.
[3]	李嘉琪,栾瑾微,张,玉,李香兰. 763例三阴性乳腺癌临床病理特征及复发、转移影响因素分析[J]. 实用肿瘤学杂志, 2019, 33(3): 244-249.
[4]	侯玉雪,李晓莉. Wnt7a与恶性肿瘤的关系及研究进展[J]. 实用肿瘤学杂志, 2019, 33(3): 271-275.
[5]	朱琳,张春霞. 纳米载药系统靶向肿瘤干细胞的研究进展[J]. 实用肿瘤学杂志, 2019, 33(3): 276-279.
[6]	李珊,赵春波,乔文波. 术中放疗在胰腺癌中的应用进展[J]. 实用肿瘤学杂志, 2019, 33(3): 280-283.
[7]	陈艳波, 孔德嘉, 张金锋, 马志刚. 乳腺癌患者CYP2D6基因多态性与他莫昔芬代谢相关性研究[J]. 实用肿瘤学杂志, 2019, 33(2): 110-114.
[8]	孙江宏, 郝明珠, 姜丹, 国飞, 李晓梅. 乳腺炎、良性增生及乳腺癌FFDM鉴别诊断思路[J]. 实用肿瘤学杂志, 2019, 33(2): 139-141.
[9]	马志杰, 王帆, 赵亚双. 乳腺癌化疗患者生存质量及影响因素分析[J]. 实用肿瘤学杂志, 2019, 33(2): 149-154.
[10]	方琳, 刘超, 张纯慧, 张艳桥. 转移性结直肠癌维持治疗的研究现状与治疗策略[J]. 实用肿瘤学杂志, 2019, 33(2): 173-178.
[11]	马质莹, 尚乃舰, 蔡妙田, 沈阳, 姜智允. 孕激素及雌激素受体阳性乳腺癌HER-2受体与钼靶影像学特征及临床病理学特征的相关性分析[J]. 实用肿瘤学杂志, 2019, 33(1): 47-51.
[12]	丁界先, 张津, 陈永刚, 王兴文综述, 王栓科审校. Wnt信号通路与肿瘤发生的研究进展[J]. 实用肿瘤学杂志, 2019, 33(1): 73-77.
[13]	邢志超综述, 麦威审校. 脂肪肉瘤潜在作用靶点的研究进展[J]. 实用肿瘤学杂志, 2019, 33(1): 82-86.
[14]	张攀, 张迪综述, 戴晓波审校. 复发鼻咽癌再程放射治疗的研究进展[J]. 实用肿瘤学杂志, 2019, 33(1): 92-96.
[15]	田洋, 吴华星. 超细鼻胃镜在消化道狭窄性疾病中的临床应用[J]. 实用肿瘤学杂志, 2018, 32(6): 550-554.

二甲双胍与不同分子亚型乳腺癌的关系

The relationship between metformin and different molecular subtypes of breast cancer

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价